Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

Presentation

Presentation: A combined fertility, embryofetal development, AAV integration and germline transmission risk study in mice with ST-920 (isaralgagene civaparvovec) for Fabry disease

Download PDF